RWA Wealth Partners LLC Sells 393,531 Shares of Pfizer Inc. (NYSE:PFE)

RWA Wealth Partners LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 59.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 272,798 shares of the biopharmaceutical company’s stock after selling 393,531 shares during the quarter. RWA Wealth Partners LLC’s holdings in Pfizer were worth $7,237,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the 4th quarter worth approximately $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC bought a new stake in Pfizer in the fourth quarter valued at approximately $32,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PFE. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Bank of America reiterated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Up 0.8 %

NYSE:PFE opened at $25.20 on Monday. The firm has a market capitalization of $142.93 billion, a P/E ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company’s 50-day simple moving average is $26.06 and its 200 day simple moving average is $26.90.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the firm posted $0.10 EPS. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.